Solstice Pharmaceuticals to sponsor and participate in the 29th European Symposium on Ultrasound Contrast Imaging in Rotterdam
Enschede, 13th December 2023
Solstice Pharmaceuticals, a leading innovator in diagnostic and therapeutic ultrasound applications, proudly announces its participation in the 29th European Symposium on Ultrasound Contrast Imaging. The event is scheduled to take place between 18th–19th January 2024, in Rotterdam, The Netherlands.
The symposium, recognised as a premier gathering for experts and professionals of ultrasound contrast imaging, offers a platform for networking, knowledge sharing, and exploring the latest advances in the field. Solstice Pharmaceuticals is thrilled to join this event both as sponsor and to engage with key clinical and research partners, fostering collaborations and advancing groundbreaking healthcare solutions.
"This symposium presents an unparalleled opportunity for us to connect with our esteemed clinical and research partners," said Jan Sigger, Chairman of the Board at Solstice Pharmaceuticals. "We are excited to engage in discussions that will further our mission of developing next generation microbubbles for diagnostic and therapeutic ultrasound applications."
Solstice Pharmaceuticals invites all attendees, partners, and interested parties to meet at the symposium's exhibition area. The team will be available to discuss collaborative opportunities, showcase their latest research, and demonstrate their commitment in driving innovation in ultrasound microbubble technology.
About Solstice Pharmaceuticals:
Solstice Pharmaceuticals is a leading innovator in the development of monodisperse microbubble technology for medical imaging & therapeutics. Our products are designed to improve the accuracy and sensitivity of ultrasound applications, enabling earlier detection and more effective treatment for a wide range of diseases.
